ABSTRACT
In HIV-seropositive individuals, the incidence of acute pancreatitis may achieve 40% per year, higher than the 2% found in the general population. Since 1996, when combined antiretroviral therapy, known as HAART (highly active antiretroviral therapy), was introduced, a broad spectrum of harmful factors to the pancreas, such as opportunistic infections and drugs used for chemoprophylaxis, dropped considerably. Nucleotide analogues and metabolic abnormalities, hepatic steatosis and lactic acidosis have emerged as new conditions that can affect the pancreas. To evaluate the role of antiretroviral drugs to treat HIV/AIDS in a scenario of high incidence of acute pancreatitis in this population, a systematic review was performed, including original articles, case reports and case series studies, whose targets were HIV-seropositive patients that developed acute pancreatitis after exposure to any antiretroviral drugs. This association was confirmed after exclusion of other possible etiologies and/or a recurrent episode of acute pancreatitis after re-exposure to the suspected drug. Zidovudine, efavirenz, and protease inhibitors are thought to lead to acute pancreatitis secondary to hyperlipidemia. Nucleotide reverse transcriptase inhibitors, despite being powerful inhibitors of viral replication, induce a wide spectrum of side effects, including myelotoxicity and acute pancreatitis. Didanosine, zalcitabine and stavudine have been reported as causes of acute and chronic pancreatitis. They pose a high risk with cumulative doses. Didanosine with hydroxyurea, alcohol or pentamidine are additional risk factors, leading to lethal pancreatitis, which is not a frequent event. In addition, other drugs used for prophylaxis of AIDS-related opportunistic diseases, such as sulfamethoxazole-trimethoprim and pentamidine, can produce necrotizing pancreatitis. Despite comorbidities that can lead to pancreatic involvement in the HIV/AIDS population, antiretroviral drug-induced pancreatitis should always be considered in the diagnosis of patients with abdominal pain and elevated pancreatic enzymes.
Subject(s)
Acquired Immunodeficiency Syndrome/drug therapy , Anti-HIV Agents/adverse effects , Antiretroviral Therapy, Highly Active/adverse effects , Pancreatitis/chemically induced , Acquired Immunodeficiency Syndrome/complications , Acute Disease , Comorbidity , Female , Humans , Male , Risk FactorsABSTRACT
In HIV-seropositive individuals, the incidence of acute pancreatitis may achieve 40% per year, higher than the 2% found in the general population. Since 1996, when combined antiretroviral therapy, known as HAART (highly active antiretroviral therapy), was introduced, a broad spectrum of harmful factors to the pancreas, such as opportunistic infections and drugs used for chemoprophylaxis, dropped considerably. Nucleotide analogues and metabolic abnormalities, hepatic steatosis and lactic acidosis have emerged as new conditions that can affect the pancreas. To evaluate the role of antiretroviral drugs to treat HIV/AIDS in a scenario of high incidence of acute pancreatitis in this population, a systematic review was performed, including original articles, case reports and case series studies, whose targets were HIV-seropositive patients that developed acute pancreatitis after exposure to any antiretroviral drugs. This association was confirmed after exclusion of other possible etiologies and/or a recurrent episode of acute pancreatitis after re-exposure to the suspected drug. Zidovudine, efavirenz, and protease inhibitors are thought to lead to acute pancreatitis secondary to hyperlipidemia. Nucleotide reverse transcriptase inhibitors, despite being powerful inhibitors of viral replication, induce a wide spectrum of side effects, including myelotoxicity and acute pancreatitis. Didanosine, zalcitabine and stavudine have been reported as causes of acute and chronic pancreatitis. They pose a high risk with cumulative doses. Didanosine with hydroxyurea, alcohol or pentamidine are additional risk factors, leading to lethal pancreatitis, which is not a frequent event. In addition, other drugs used for prophylaxis of AIDS-related opportunistic diseases, such as sulfamethoxazole-trimethoprim and pentamidine, can produce necrotizing pancreatitis. Despite comorbidities that can lead to pancreatic involvement in the HIV/AIDS population, antiretroviral drug-induced pancreatitis should always be considered in the diagnosis of patients with abdominal pain and elevated pancreatic enzymes.
Em HIV-soropositivos, a incidência de pancreatite aguda pode chegar até 40% ao ano, o que é consideravelmente maior que na população geral, cuja incidência é de 2%. A partir de 1996, com a introdução da terapia antirretroviral combinada, conhecida pela sigla HAART (highly active antiretroviral therapy), o espectro de fatores nocivos ao pâncreas, como infecções oportunistas e uso de drogas para sua quimioprofilaxia, diminuiu consideravelmente. Análogos nucleotídeos e anormalidades metabólicas, esteatose hepática e acidose láctica despontaram como novas condições que podem acometer o pâncreas. A fim de avaliar o papel das drogas antirretrovirais para tratamento do HIV/AIDS na incidência elevada de pancreatite aguda nessa população, foi realizada revisão sistemática, com inclusão de artigos originais, relatos e séries de caso, cujos alvos de estudo eram pacientes HIV-soropositivos que evoluíram com pancreatite aguda após exposição a alguma das drogas que compõem o esquema antirretroviral. Essa associação foi confirmada após exclusão de outras possíveis etiologias e/ou recorrência do episódio de pancreatite aguda após reexposição ao fármaco suspeito. Zidovudina, efavirenz e os inibidores de protease são suspeitos de levar a uma pancreatite secundária à hiperlipidemia. Já os análogos nucleotídeos da transcriptase reversa, apesar de serem potentes inibidores da replicação viral, possuem grande espectro de efeitos colaterais, entre eles a mielotoxicidade e a pancreatite aguda. Didanosina, zalcitabina e estavudina já foram reportados como produtores de pancreatite crônica e aguda, tendo risco elevado com dose cumulativa. Didanosina com hidroxiureia, álcool ou pentamidina são fatores de risco adicionais, podendo induzir a uma pancreatite fatal, embora pouco frequente. Além disso, outras drogas usadas para profilaxia de doenças oportunistas relacionadas à AIDS, como sulfametoxazol-trimetoprima e pentamidina, podem produzir pancreatite necrotizante. Apesar das comorbidades que podem levar ao acometimento pancreático na população com HIV/AIDS, pancreatite medicamentosa desencadeada por drogas antirretrovirais sempre deve ser considerada no diagnóstico diferencial desses pacientes que se apresentam com dor abdominal e elevação das enzimas pancreáticas.
Subject(s)
Female , Humans , Male , Acquired Immunodeficiency Syndrome/drug therapy , Anti-HIV Agents/adverse effects , Antiretroviral Therapy, Highly Active/adverse effects , Pancreatitis/chemically induced , Acquired Immunodeficiency Syndrome/complications , Acute Disease , Comorbidity , Risk FactorsABSTRACT
Gestantes podem precisar ser submetidas a exames radiológicos para um diagnóstico preciso e conduta correta. Os métodos mais difundidos são aqueles com pouco ou nenhum efeito sobre o feto, como a ultrassonografia e, mais recentemente, a ressonância magnética. Os exames radiológicos são geralmente relegados a um segundo plano e, eventualmente, descartados ou adiados em razão da apreensão gerada pelos potenciais riscos à saúde do feto. No entanto, um diagnóstico postergado ou perdido por causa da não utilização desses exames pode ser mais nocivo à saúde materna e do próprio feto do que os possíveis riscos associados ao uso da radiação ionizante. Conhecer os princípios e efeitos biológicos das radiações ionizantes, bem como os limiares de doses associadas a efeitos deletérios sobre o embrião e o feto, permite medir os riscos e justificar a utilização de determinados métodos radiológicos em benefício da gestante. Com base numa revisão de literatura, tivemos o propósito de orientar médicos, especialistas ou não, para fornecer melhores informações e esclarecimentos a suas pacientes quanto aos riscos e benefícios do uso de métodos de diagnóstico por imagem durante a gestação.
Pregnants may need to undergo radiological examinations for a right diagnosis and an accurate conduct. The most spread methods are those that have less or none effect on the fetus, such as ultrasound and, more recently, magnetic resonance imaging. The radiological examinations are usually relegated to a second plan and, occasionally, discarded or postponed because of the apprehension caused by the potential risks to the fetal health. However, a postponed or missed diagnosis, for not using these tests, can be more harmful to the pregnant?s health and the fetus itself than the possible risks associated with ionizing radiation. Knowing the principles and biological effects of ionizing radiation, as well as the threshold levels associated with deleterious effects on embryo and fetus, allows measuring the risks and justify the use of certain radiological methods for the benefit of the pregnant. Based on the literature review, we purposed to advise doctors, specialists or not, to provide better information and explanations to their patients about risks and benefits of using methods of diagnostic imaging during pregnancy.